Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop -

NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) -- supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians -- today said that updated statistics reported at the 11th International Myeloma Workshop in Greece demonstrate improved survival for a wide range of myeloma patients. Among the findings, in patients who had relapsed after one or more previous treatments:

    -- REVLIMID(R) (lenalidomide) plus the steroid dexamethasone showed an

       unprecedented median survival of nearly three years (35 months) for

       patients previously treated with multiple myeloma in updated data

       pooled from two large randomized controlled Phase III trials evaluating

       more than 700 patients from nearly 100 clinical sites worldwide.


    -- VELCADE(R) (bortezomib), combined with cyclophosphamide and prednisone

       in an open label Phase II trial evaluating 13 patients demonstrated an

       overall response rate of 93 percent. At one year, 100 percent of

       patients were alive.


    -- And combining VELCADE plus REVLIMID (with a steroid) showed a response

       rate of 68 percent in a pilot study of heavily pretreated patients.

"It was 15 years ago this month that my husband Brian Novis lost his battle with myeloma, and the progress since that time is truly remarkable," said Susie Novis, president and co-founder of the IMF. "Brian was diagnosed when he was just 33 years old and lived only four years past his diagnosis. Today we have multiple options for treatment, and for many patients survival is being measured in years, not months, with an excellent quality of life."

The International Myeloma Workshop brings together myeloma experts from all over the world to review the lates
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , ... announced today that T. (Teo) Forcht Dagi ... the company,s Board of Directors. " Teo ... career in neurosurgery, medical innovation and venture capital," said ... extremely delighted to add his clinical, strategic, and entrepreneurial expertise ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... PASO ROBLES, Calif. , Aug. 29, 2014 /PRNewswire/ ... launch of its new website design . The ... an overhaul that showcases the company,s new services and ... By implementing a new streamlined design, viewers can ... deliver metrics for health care practices and create a ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3PMDS Announces New Website 2
... SAN DIEGO, Dec. 21, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Executive Officer, will host a conference call ... Eastern Time (5:30 a.m. Pacific Time) to provide an update ... Food and Drug Administration (FDA) for the lorcaserin New Drug ...
... YORK, Dec. 21, 2010 Reportlinker.com announces that ... its catalogue: U.S. Preclinical ... http://www.reportlinker.com/p0350308/US-Preclinical-Animal-Imaging-Systems-Market.html This research ... Animal Imaging Systems Market since 2006. It examines ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 2Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 3
(Date:8/30/2014)... 30, 2014 Daily Gossip reveals in its ... Him Desire You program, who shows a unique formula to ... of this method says that the program goes beyond mere ... Him Desire You review indicates that the program was created ... and his great techniques to make a man feel emotionally ...
(Date:8/30/2014)... 30, 2014 The term nutraceuticals ... Pharameuticals. Nutraceuticals is a source of healthy-dietary supplements ... natural food sources. Nutraceutical ingredients have certain curative ... human body. Nutraceutical health products include factors such ... and more. Although nature is the most bountiful ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Teens who eat less salt lower their long-term risk for high ... finding stems from a computerized projection of what would happen if ... salt from their daily consumption of common processed foods. "Reducing ... that we eat could mean that teenagers live many more years ...
... , SATURDAY, Nov. 13 (HealthDay News) -- People who ... increased risk themselves for the potentially deadly heart rhythm ... data from 4,421 participants in the long-term Framingham Heart ... start of the study. Between 1968 and 2007, 440 ...
... say that physicians might be drawing conclusions too soon ... whose bodies were for a day initially chilled into ... as therapeutic hypothermia, is one of the few medical ... stoppages, with brain recovery usually assessed three days after ...
... HealthDay Reporter , FRIDAY, Nov. 12 (HealthDay News) -- ... have made significant discoveries in the past year that might ... disease in its tracks. That,s some good ... in 1991 as a joint project between the International Diabetes ...
... Northwestern Memorial Hospital recently implanted a patient with two ... available for study in humans. VADs are designed to ... or both (BiVAD) at once. This is the first ... the left and right ventricles anywhere in North Americaa ...
... (HealthDay News) -- A minor gene variation may be associated with ... study has found. In a recent experiment, Martin Reuter, of ... with this variation in a gene known as COMT gave away ... people with another variation of the gene. The COMT gene ...
Cached Medicine News:Health News:Study Urges Teens to Cut Down on Salt 2Health News:Study suggests physicians wait longer for brain recovery after hypothermia Rx in cardiac arrest 2Health News:Study suggests physicians wait longer for brain recovery after hypothermia Rx in cardiac arrest 3Health News:Diabetes Research Made Significant Strides in Past Year 2Health News:Diabetes Research Made Significant Strides in Past Year 3Health News:Small assist device used in emergency case as twin, heart booster pumps for first time in US 2
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
Medicine Products: